Netherlands· NL-3eee31c55b74

Qinlock 50 mg tabletten

A ripretinib product containing ripretinib, registered in Netherlands by Deciphera Pharmaceuticals (Netherlands) B.V.. The same ATC class is registered in 13 of our 19 countries.

ATC L01EX19

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about ripretinibAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Ripretinib is registered in 13 of 19 countries.

Countries holding a registration under ATC L01EX19 (ripretinib), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
8 of them publish a price we can compare per daily dose

Search ripretinib products by name

Ripretinib · ATC L01EX19

13 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Icelandprice
Ireland
Netherlands
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ripretinib costs, country by country.

Normalised to the WHO defined daily dose (0.15 g), the median price runs from $0.72 in France to $744.16 in Switzerland — a ×1040 gap.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Ripretinib · price per daily dose (0.15 g)

USD · FX 28 Sept 2026

CH Switzerland$744.16
FR France$0.72

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: RIPRETINIB
Manufacturer: Deciphera Pharmaceuticals (Netherlands) B.V.
Country: Netherlands (NL)
ATC code: L01EX19
ATC class: Ripretinib
Defined daily dose: 0.15 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/21/1569

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

133 interactions on record for ripretinib.

Graded by severity as the source publishes them — 12 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check ripretinib against other medicines How interaction checks work

Ripretinib · interactions on record

133 records

12 severe
121 moderate

Most severe, free to view

KetoconazoleH02CA03severe
ClarithromycinJ01FA09severe
KetoconazoleJ02AB02severe
Darunavir and cobicistatJ05AR14severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ripretinib in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ripretinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

Iceland · Qinlock
Liechtenstein · Qinlock
Norway · Qinlock

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/8c757a4c-b214-4195-b3c2-93ec9d79f120
GET /v1/drugs/8c757a4c-b214-4195-b3c2-93ec9d79f120?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/qinlock-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Ripretinib",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp127358",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSPOVIDON (E 1202)",
    "HYPROMELLOSEACETAATSUCCINAAT",
    "LACTOSE 1-WATER",
    "MAGNESIUMSTEARAAT (E 470b)",
    "SILICIUMDIOXIDE, GEHYDRATEERD (E 551)"
  ],
  "substances": [
    "RIPRETINIB"
  ],
  "leaflet_url": null,
  "authorised_at": "2021/11/18",
  "procedure_number": "EMEA/H/C/005614",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/21/1569",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about ripretinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console